All In Biotech

Drug Trial Radar · NCT03370133

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 567 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

567

Actual

Start

Dec 6, 2017

Primary completion

Jan 8, 2019

Study completion Dec 13, 2019

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Dec 12, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

Conditions

  • Chronic Plaque Psoriasis
  • Moderate to Severe Chronic Plaque Psoriasis
  • Psoriatic Arthritis

Interventions

  • BimekizumabDrug

    Bimekizumab will be provided at pre-specified time intervals.

  • UstekinumabDrug

    Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.

  • PlaceboOther

    Subjects will receive Placebo at pre-specified time points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16Time frame: Week 16
  2. Percentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16Time frame: Week 16

Locations

105 sites in 11 countries. Site status is shown where the registry gives one.

  • Ps0009 946

    Phoenix, Arizona

  • Ps0009 910

    Bakersfield, California

  • Ps0009 919

    San Diego, California

  • Ps0009 906

    Boca Raton, Florida

  • Ps0009 909

    Boynton Beach, Florida

  • Ps0009 912

    Coral Gables, Florida

  • Ps0009 907

    Miami, Florida

  • Ps0009 903

    Ocala, Florida

  • Ps0009 921

    Ormond Beach, Florida

  • Ps0009 918

    Tampa, Florida

  • Ps0009 941

    Alpharetta, Georgia

  • Ps0009 911

    Plainfield, Indiana

  • Ps0009 900

    West Des Moines, Iowa

  • Ps0009 905

    Overland Park, Kansas

  • Ps0009 922

    Baton Rouge, Louisiana

  • Ps0009 917

    Troy, Michigan

  • Ps0009 915

    St Louis, Missouri

  • Ps0009 958

    Omaha, Nebraska

  • Ps0009 901

    Portsmouth, New Hampshire

  • Ps0009 908

    East Windsor, New Jersey

  • Ps0009 923

    Albuquerque, New Mexico

  • Ps0009 913

    New York, New York

  • Ps0009 920

    Portland, Oregon

  • Ps0009 924

    Houston, Texas

  • Ps0009 914

    San Antonio, Texas

  • Ps0009 004

    Fremantle, Australia

  • Ps0009 005

    Phillip, Australia

  • Ps0009 002

    Westmead, Australia

  • Ps0009 009

    Woolloongabba, Australia

  • Ps0009 050

    Brussels, Belgium

  • Ps0009 052

    Liège, Belgium

  • Ps0009 051

    Loverval, Belgium

  • Ps0009 673

    Halifax, Canada

  • Ps0009 652

    Oakville, Canada

  • Ps0009 651

    Richmond Hill, Canada

  • Ps0009 650

    Surrey, Canada

  • Ps0009 653

    Toronto, Canada

  • Ps0009 657

    Waterloo, Canada

  • Ps0009 218

    Bonn, Germany

  • Ps0009 209

    Darmstadt, Germany

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.